ABEONA THERAPEUTICS

Company snapshot

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Abeona’s fully integrated cell and gene therapy cGM

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ABEONA THERAPEUTICS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ABEONA THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   LZRSE-Col7A1 Engineered Autologous Epidermal Sheets — Phase 2

2. May 23, 2026 Clinical update

   EB-101 — Phase 3

3. May 23, 2026 Clinical update

   EB-101 Surgical application of RDEB wounds — Phase 3

4. May 23, 2026 Clinical update

   UX111 — Phase 3

5. May 23, 2026 Clinical update

   ofloxacin — Phase 3

View all clinical trial activity →

• What is ABEONA THERAPEUTICS?

  ABEONA THERAPEUTICS is a pharma organization headquartered in Cleveland, USA. It trades on NYSE under ticker ABEO. Primary therapeutic focus areas include MPS IIIA, Epidermolysis Bullosa, Onychomycosis, Epidermolysis Bullosa Dystrophica, Diabetic Foot Ulcers. NovaPharmaNews links

• Is ABEONA THERAPEUTICS publicly traded?

  Yes. ABEONA THERAPEUTICS is listed with ticker ABEO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ABEONA THERAPEUTICS develop or market?

  We link 3 drug profile(s) where ABEONA THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/abeona-therapeutics-inc#company-drugs.

• What are the latest developments for ABEONA THERAPEUTICS?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ABEONA THERAPEUTICS focus on?

  ABEONA THERAPEUTICS focuses on MPS IIIA, Epidermolysis Bullosa, Onychomycosis based on our analysis of their pipeline programs and drug development activities.